Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Completed · Phase 2 · Has a placebo group

Conditions studied: High Cardiovascular Risk, Hypertension

In brief

The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Key facts

Study ID
NCT06272487
Run by
Alnylam Pharmaceuticals
People needed
375
Starts
2024-02-29
Expected to finish
2025-12-01
Last updated by the study team
2026-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.